Paper Details
- Home
- Paper Details
Pigmentary changes in patients treated with targeted anticancer agents: A systematic review and meta-analysis.
Author: BelumViswanath R, DaiJulia, LacoutureMario E, SibaudVincent, WuShenhong
Original Abstract of the Article :
BACKGROUND: The discovery of signaling networks that drive oncogenic processes has led to the development of targeted anticancer agents. The burden of pigmentary adverse events from these drugs is unknown. OBJECTIVE: To conduct a systematic review and meta-analysis of published clinical trials and ...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元:
https://pubmed.ncbi.nlm.nih.gov/28918974
データ提供:米国国立医学図書館(NLM)
Pigmentary Changes: A Side Effect of Targeted Anticancer Agents
Oncology, the study of cancer, is constantly evolving with the development of new targeted agents. While these agents offer hope for effective treatment, it is crucial to understand their side effects. This research focused on pigmentary changes, a common side effect of targeted anticancer agents. The authors conducted a systematic review and meta-analysis of clinical trials to determine the incidence and risk of these changes.
High Incidence of Pigmentary Changes in Targeted Cancer Therapy
The study found a significant incidence of pigmentary changes, affecting both skin and hair, in patients receiving targeted cancer therapy. The overall incidence of pigmentary changes in the skin was 17.7%, while the incidence in hair was 21.5%. These findings suggest that patients undergoing targeted cancer therapy have a substantial risk of developing pigmentary changes.
Implications for Patient Counseling and Management
The research emphasizes the need for comprehensive patient counseling regarding the potential for pigmentary changes during targeted cancer therapy. This information will empower patients to be aware of the potential side effects and seek appropriate management strategies. It's like navigating a desert: knowing about potential sandstorms helps you prepare for the journey ahead.
Dr.Camel's Conclusion
Just as a desert traveler must be prepared for the sun's intensity, patients undergoing targeted cancer therapy should be informed about the potential for pigmentary changes. This research provides valuable insight into the potential side effects, enabling doctors and patients to make informed decisions about treatment and management.
Date :
- Date Completed 2017-11-02
- Date Revised 2018-12-02
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.